Nature Communications (Oct 2016)
PARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylation
- Hiroshi Iwata,
- Claudia Goettsch,
- Amitabh Sharma,
- Piero Ricchiuto,
- Wilson Wen Bin Goh,
- Arda Halu,
- Iwao Yamada,
- Hideo Yoshida,
- Takuya Hara,
- Mei Wei,
- Noriyuki Inoue,
- Daiju Fukuda,
- Alexander Mojcher,
- Peter C. Mattson,
- Albert-László Barabási,
- Mark Boothby,
- Elena Aikawa,
- Sasha A. Singh,
- Masanori Aikawa
Affiliations
- Hiroshi Iwata
- Cardiovascular Division, Center for Interdisciplinary Cardiovascular Sciences, Brigham and Women’s Hospital, Harvard Medical School
- Claudia Goettsch
- Cardiovascular Division, Center for Interdisciplinary Cardiovascular Sciences, Brigham and Women’s Hospital, Harvard Medical School
- Amitabh Sharma
- Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School
- Piero Ricchiuto
- Cardiovascular Division, Center for Interdisciplinary Cardiovascular Sciences, Brigham and Women’s Hospital, Harvard Medical School
- Wilson Wen Bin Goh
- Cardiovascular Division, Center for Interdisciplinary Cardiovascular Sciences, Brigham and Women’s Hospital, Harvard Medical School
- Arda Halu
- Cardiovascular Division, Center for Interdisciplinary Cardiovascular Sciences, Brigham and Women’s Hospital, Harvard Medical School
- Iwao Yamada
- Cardiovascular Division, Center for Interdisciplinary Cardiovascular Sciences, Brigham and Women’s Hospital, Harvard Medical School
- Hideo Yoshida
- Cardiovascular Division, Center for Interdisciplinary Cardiovascular Sciences, Brigham and Women’s Hospital, Harvard Medical School
- Takuya Hara
- Cardiovascular Division, Center for Interdisciplinary Cardiovascular Sciences, Brigham and Women’s Hospital, Harvard Medical School
- Mei Wei
- Department of Microbiology and Immunology, Vanderbilt University School of Medicine
- Noriyuki Inoue
- Cardiovascular Division, Center for Interdisciplinary Cardiovascular Sciences, Brigham and Women’s Hospital, Harvard Medical School
- Daiju Fukuda
- Cardiovascular Division, Center for Interdisciplinary Cardiovascular Sciences, Brigham and Women’s Hospital, Harvard Medical School
- Alexander Mojcher
- Cardiovascular Division, Center for Interdisciplinary Cardiovascular Sciences, Brigham and Women’s Hospital, Harvard Medical School
- Peter C. Mattson
- Cardiovascular Division, Center for Interdisciplinary Cardiovascular Sciences, Brigham and Women’s Hospital, Harvard Medical School
- Albert-László Barabási
- Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School
- Mark Boothby
- Department of Microbiology and Immunology, Vanderbilt University School of Medicine
- Elena Aikawa
- Cardiovascular Division, Center for Interdisciplinary Cardiovascular Sciences, Brigham and Women’s Hospital, Harvard Medical School
- Sasha A. Singh
- Cardiovascular Division, Center for Interdisciplinary Cardiovascular Sciences, Brigham and Women’s Hospital, Harvard Medical School
- Masanori Aikawa
- Cardiovascular Division, Center for Interdisciplinary Cardiovascular Sciences, Brigham and Women’s Hospital, Harvard Medical School
- DOI
- https://doi.org/10.1038/ncomms12849
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 19
Abstract
Signalling pathways that mediate macrophage activation in disease are poorly understood. Here the authors show that inhibition of PARP9 and/or activation of PARP14 may attenuate macrophage-mediated vascular diseases, and also provide new insight into the development of effective therapies for other inflammatory disorders.
